Human Immunoglobulin G Recognizing Fibrinogen-Binding Surface Proteins Is Protective against both <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i> Infections In Vivo

John Vernachio, Arnold S. Bayer, Brenda Ames, Dawn Bryant, Bradley D. Prater, Peter J. Syribeys, Elena Gorovits, Joseph M. Patti

Antimicrobial Agents and Chemotherapy · 2006 · 69 citations · 21 references

DOIFull text

Open access

Concepts

Abstract

A human donor-selected immunoglobulin G for intravenous injection (IGIV) product with elevated titers against the staphylococcal fibrinogen-binding MSCRAMM proteins ClfA and SdrG (INH-A21) was tested in vitro and in vivo. INH-A21 contained a significantly increased ability to inhibit the fibrinogen-binding activity of recombinant forms of both ClfA and SdrG. Evaluation of the opsonizing potential of INH-A21 was evaluated using fluorescently labeled bacteria; this assay indicated an increase in phagocytic activity compared to normal IGIV. The prophylactic efficacy of INH-A21 against an intraperitoneal challenge of methicillin-resistant Staphylococcus epidermidis (MRSE) was evaluated in a neonatal rat model. INH-A21 was also evaluated for prophylactic and therapeutic efficacy in a rabbit model of catheter-induced aortic valve infective endocarditis caused by either MRSE or methicillin-resistant Staphylococcus aureus (MRSA). Results from the in vivo models demonstrated potent prophylactic and therapeutic efficacy against both MRSE and MRSA. These data suggest that INH-A21 may be an important tool for the prevention and treatment of staphylococcal infections, especially in high-risk populations.

References

21